DELRAY BEACH, FL – November 25, 2024 – Genetic Institutes of America, Inc. (GIA) now offers Oncuria Predict, a groundbreaking urine-based test that empowers urologists to make more informed decisions about bladder cancer treatment. Oncuria predicts a patient’s likelihood of responding to BCG therapy, a key factor in personalizing treatment plans.

While cystoscopy remains the standard for diagnosing bladder cancer, Oncuria offers a valuable tool for optimizing treatment strategies. By identifying patients unlikely to benefit from BCG therapy, urologists can identify those with a higher chance of success. This test not only improves patient outcomes but also helps manage the global scarcity of BCG resources.

Oncuria analyzes a panel of protein biomarkers in urine, providing valuable insights into a patient’s unique situation. Clinical studies have demonstrated Oncuria’s high accuracy in predicting BCG response.

With limited BCG manufacturing facilities worldwide, Oncuria is a crucial test for optimizing treatment strategies. Identifying patients unlikely to benefit from BCG therapy allows physicians to identify those with a higher chance of success. This test not only improves patient outcomes but also helps manage the global scarcity of BCG resources.

“Oncuria is a valuable addition to the options available to urologists considering BCG therapy for bladder cancer patients,” said Robert Cardwell, Chief Strategy Officer at the Genetic Institute of America. “By adding Oncuria to our testing menu of offerings, GIA is leading the way in support for physicians navigating the challenges of BCG therapy by allowing them to provide targeted, effective care to their patients.”